ArticleInfection and drug resistance2021
Bloodstream Infections Caused by Carbapenem-Resistant
Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Pooled it
- Pooled it
- Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-ResistantMicrobiology spectrum · 2022Pooled it
- Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance.BMC infectious diseases · 2021Trial
- Real-World Therapy with Eravacycline for Complex Infections Caused by Carbapenem-Resistant Pathogens with a Focus on Patients with Severe Burns.Infectious diseases and therapy · 2026Article
- Procalcitonin kinetics in Gram-negative bloodstream infections and its value for infection management.Journal of medical microbiology · 2026Article
- Clinical Outcomes of Bloodstream Infections in Liver Transplant Recipients: A Ten-Year Single-Center Retrospective Analysis, from Türkiye.Antibiotics (Basel, Switzerland) · 2026Article
- Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026Article
- Machine learning-based prediction of bloodstream infection in rectal carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports.Journal of blood medicine · 2026Article
- Regional surveillance of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- O2a O-antigen type and sepsis in invasiveFrontiers in cellular and infection microbiology · 2026Article
- Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis.BMC infectious diseases · 2025Article
- Outcomes of Implementing a Multidimensional Antimicrobial Stewardship Program in a Medical Ward in a Third-Level University Hospital in Northern Italy.Antibiotics (Basel, Switzerland) · 2025Article
- REL/DPA/AVI method: a novel approach for rapid detection of carbapenemase-producing Enterobacterales directly from positive blood cultures based on optical density.Journal of clinical microbiology · 2025Article
- Early appropriate therapy with polymyxin B reduces the mortality in burn sepsis caused by carbapenem-resistant gram-negative bacteria: a retrospective analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025Article
- Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCarbapenem-resistant PATIENTS AND
methodsWe investigated patients with CRE BSIs from 18 hospitals across nine Chinese provinces from January to December 2019. Data were collected from the medical records according to a pre-established questionnaire. Antimicrobial susceptibility testing and DNA sequencing were performed to investigate the characteristics of isolates.
resultsA total of 208 patients enrolled; the overall 30-day mortality rate was 46.2%. The causative pathogen was carbapenem-resistant
conclusionReducing the mortality of CRE BSIs need to comprehensively consider whether the antimicrobials were used appropriately, together with infection severity and CRE strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.